Patent: 9,688,760
✉ Email this page to a colleague
Summary for Patent: 9,688,760
Title: | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains |
Abstract: | The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20.times.CD3 or a CD19.times.CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof. |
Inventor(s): | Kufer; Peter (Munich, DE), Nagorsen; Dirk (Munich, DE), Scheele; Juergen (Munich, DE), Zugmaier; Gerhard (Munich, DE), Klinger; Matthias (Gilching, DE), Hoffmann; Patrick (Bad Heilbrunn, DE), Naegele; Virginie (Munich, DE), Dopfer; Elaine-Pashupati (Munich, DE) |
Assignee: | AMGEN RESEARCH (MUNICH) GMBH (Munich, DE) |
Application Number: | 14/176,091 |
Patent Claims: | see list of patent claims |
Details for Patent 9,688,760
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2033-02-08 |
Amgen, Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | 12/03/2014 | ⤷ Try a Trial | 2033-02-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |